Pharmacology of different progestogens: the special case of drospirenone

References

• Henzl M R, Edwards J A. Pharmacology of progestins: 17α-hydroxyprogesterone derivatives and progestins of the first and second generation. Progestins and Antiprogestins in Clinical Practice, R Sitruk-Ware, D R Mishell, Jr. Marcel Dekker, New York 2000; 101–132
   Google Scholar
• Stanczyk F Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocrin Metab Disord 2002; 3: 211–224
   PubMedGoogle Scholar
• Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6–15
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–491
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron J A, Correira N, et al. Breast cancer risk following long term oestrogen- and oestrogen–progestin replacement therapy. Int J Cancer 1999; 81: 339–344
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21: 865–883
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277–283
   PubMed Web of Science ®Google Scholar
• Wright F, Giacomini M, Riahi M, . Antihormone activity of progesterone and progestins. Progesterone and Progestins, C W Bardin, E Milgröm, P Mauvais-Jarvis, et al. Raven Press Books, New York 1983; 121–134
   Google Scholar
• Corvol P, Elkik F, Feneant M, . Effect of progesterone and progestins on water and salt metabolism. Progesterone and Progestins, C W Bardin, E Milgröm, P Mauvais-Jarvis, et al. Raven Press Books, New York, 179–186
   Google Scholar
• Oelkers W, Foidart J M, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821
   PubMed Web of Science ®Google Scholar
• Persson I, Adami H, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J 1989; 298: 147–151
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestins in hormonal replacement therapy and prevention of endometrial disease. Progestins and Antiprogestins in Clinical Practice, R Sitruk-Ware, D R Mishell, Jr. Marcel Dekker, New York 2000; 269–277
   Google Scholar
• Sturdee D W, Barlow D H, Ulrich L G, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogens/progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet 1994; 344: 979–982
   PubMed Web of Science ®Google Scholar
• Russo J, Tay L K, Russo I H. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2: 5–73
   PubMedGoogle Scholar
• Conneely O M, Lydon J P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000; 65: 571–577
   PubMed Web of Science ®Google Scholar
• Oelkers W K. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids 1996; 61: 166–171
   PubMed Web of Science ®Google Scholar
• Oelkers W, Helmerhorst F M, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin–angiotensin–aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–213
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 217: 255–261
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000; 65: 651–658
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI trial. Effects of androgen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin (PEPI) Trial. JAMA 1995; 273: 199–208
   PubMed Web of Science ®Google Scholar
• Stout R W, Bierman E L, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975; 36: 319–327
   PubMed Web of Science ®Google Scholar
• Chait A, Bierman E L, Albers J J. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 1979; 64: 1309–1319
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and HRT. Steroids 2003; 68: 907–913
   PubMed Web of Science ®Google Scholar
• Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol 1990; 163: 2153–2159
   PubMed Web of Science ®Google Scholar
• Winneker R C, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003; 68: 915–920
   PubMed Web of Science ®Google Scholar
• Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 2003; 6(Suppl 2)17–23
   PubMedGoogle Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68: 891–905
   PubMed Web of Science ®Google Scholar
• Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999; 13: 316–326
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide S S, Tsong Y Y, et al. Nestorone®: a progestin with a unique pharmacological profile. Steroids 2000; 65: 629–636
   PubMed Web of Science ®Google Scholar
• Tuba Z, Bardin C W, Dancsi A, et al. Synthesis and biological activity of a new progestogen, 16-methylene-17α-hydroxy-18-methyl-10-norpregn-4-ene-3,20-dione acetate. Steroids 2000; 65: 266–274
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier H, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761: 311–335
   PubMed Web of Science ®Google Scholar
• Elger W, Steinbeck H, Schillinger E, . Endocrine-pharmacological profile of gestodene. Gestodene. Development of a New Gestodene-containing Low-dose Oral Contraceptive, M Elstein, et al. Parthenon Publishing, Carnforth, UK 1987; 19–33
   Google Scholar
• Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6(Suppl 3)49–54
   PubMedGoogle Scholar
• Schuermann R, Holler T, Brenda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7: 189–196
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004; 7: 103–111
   PubMed Web of Science ®Google Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1–19
   PubMed Web of Science ®Google Scholar
• Schindler A E. Differential effects of progestins on hemostasis. Maturitas 2003; 46(Suppl 1)S31–S37
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lundeen S G, Zhu Y, Carver J M, Winneker R C. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000; 65: 637–643
   PubMed Web of Science ®Google Scholar